Children with atopic dermatitis show clinical improvement after Lactobacillus exposure
- 19 March 2015
- journal article
- clinical trial
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 45 (4), 779-787
- https://doi.org/10.1111/cea.12489
Abstract
The role of probiotics in the treatment of atopic dermatitis (AD) is not clearly established. Further clinical trials with new probiotic formulations are warranted.To assess the effects of Lactobacillus paracasei (LP) and Lactobacillus fermentum (LF), and their mixture on the disease severity, quality of life, and immune biomarkers of children with AD.A double-blind, prospective, randomized placebo-controlled study was conducted on 220 children aged 1-18 years with moderate-to-severe AD (Trial number: NCT01635738). The children were randomized to receive LP, LF, LP + LF mixture, and placebo for 3 months. Changes in severity scoring of atopic dermatitis (SCORAD), Family Dermatology Life Quality Index (FDLQI), and Children's Dermatology Life Quality Index (CDLQI) scores in the different groups and at different visits were evaluated. Skin prick tests, levels of IgE, IFN-γ, IL-4, TGF-β, and TNF-α, and urine biomarkers were also evaluated.Children who received LP, LF, and LP + LF mixture showed lower SCORAD scores than the placebo group (P < 0.001), and this difference remained even at 4 months after discontinuing the probiotics. The FDLQI and CDLQI scores were lower in the LP, LF, and LP + LF mixture group than in the placebo group (P = 0.02 and 0.03). IgE, TNF-α, urine eosinophilic protein X, and 8-OHdG levels decreased, whereas IFN-γ and TGF-β increased in the probiotic groups, but these did not reach statistical significance except for IL-4 (P = 0.04). In subgroup analyses, SCORAD scores significantly decreased after probiotic treatment especially in children younger than age 12, with breastfeeding > 6 months, and with mite sensitization (P < 0.001).Supplementation of a probiotic mixture of LP and LF is associated with clinical improvement in children with AD.Keywords
Funding Information
- GenMont Biotech Inc
- National Science Council (NSC 97-2314-B-192-001-MY2)
This publication has 35 references indexed in Scilit:
- Preventative and Therapeutic Probiotic Use in Allergic Skin Conditions: Experimental and Clinical FindingsBioMed Research International, 2013
- Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infantJournal of Allergy and Clinical Immunology, 2012
- Probiotic Therapy as a Novel Approach for Allergic DiseaseFrontiers in Pharmacology, 2012
- Probiotics and allergy in children - An update reviewPediatric Allergy and Immunology, 2010
- Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double‐blind, randomized, placebo‐controlled trialPediatric Allergy and Immunology, 2010
- Randomized, placebo‐controlled trial of Lactobacillus rhamnosus GG as treatment of atopic dermatitis in infancyAllergy, 2007
- No effects of probiotics on atopic dermatitis in infancy: a randomized placebo‐controlled trialClinical and Experimental Allergy, 2006
- Effects of probiotics on atopic dermatitis: a randomised controlled trialArchives of Disease in Childhood, 2005
- Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double‐blind placebo‐controlled trialAllergy, 2004
- Severity Scoring of Atopic Dermatitis: The SCORAD IndexDermatology, 1993